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a b s t r a c t
Identifying HCV drug resistance mutations (DRMs) is increasingly important as new direct acting
antiviral therapies (DAA) become available. Tagged pooled pyrosequencing (TPP) was originally
developed as cost-effective approach for detecting low abundance HIV DRMs. Using 127 HCV-positive
samples from a Canadian injection drug user cohort, we demonstrated the suitability and efﬁciency of
TPP for evaluating DRMs in HCV NS5B gene. At a mutation identiﬁcation threshold of 1%, no nucleoside
inhibitor DRMs were detected among these DAA naïve subjects. Clinical NS5B resistance to non-
nucleoside inhibitors and interferon/ribavirin was predicted to be low within this cohort. S282T
mutation, the primary mutation selected by sofosbuvir in vitro, was not identiﬁed while S282G/C/R
variants were detected in 9 subjects. Further characterization on these new S282 variants using in silico
molecular modeling implied their potential association with resistance. Combining TPP with in silico
analysis detects NS5B polymorphisms that may explain differences in treatment outcomes.
Crown Copyright & 2014 Published by Elsevier Inc. All rights reserved.
Introduction
Hepatitis C is a chronic disease that affects approximately 150
million people worldwide (WHO, 2014) with 250,000 people in
Canada infected (Shah et al., 2013). Traditional HCV treatment
employed a combination of ribavirin (RBV) and interferon (IFN), which
had varying levels of efﬁcacy against different HCV genotypes (Myers
et al., 2012). New direct acting antivirals (DAAs) offer the promise of
better outcomes with many fewer side effects (Afdhal et al., 2014a,
2014b). However, the presence of drug resistance mutations can affect
treatment outcomes and baseline testing for the Q80K mutation is
now recommended for patients infected with genotype 1a virus
undergoing Simepravir treatment (Palanisamy et al., 2013).
Resistance to the DAA is a genuine concern due to the unique
life cycle of the virus. HCV is a positive-strand, 1104-nucleotide
RNA virus that replicates through a negative-strand intermediate
using a viral RNA-dependent RNA polymerase NS5B. The polymer-
ase lacks error-correction and has an in vivo mutation rate of
2.5105 mutations per nucleotide per replication (Ribeiro et al.,
2012). As HCV has a high replication rate, producing as many as
1012 virions per day, one could predict that every position in the
virus would be mutated daily with the certainty of multiple
mutations among the genomes (Neumann et al., 1998). It is this
viral diversity, in the setting of naturally occurring HCV variants,
that creates mutant viruses selected under drug pressure (Rong
et al., 2010; Zeuzem, 1999).
Early DAAs, such as telaprevir, targeted the viral protease (NS3–
NS4A); however, these agents have a low genetic barrier to resistance
and HCV polymorphisms in treatment-naïve individuals confers
in vitro resistance (Bartels et al., 2013; Kuntzen et al., 2008). There
are several other classes of DAAs, including the recently approved
sofosbuvir, that target either the active or allosteric sites of NS5B
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(Mayhoub, 2012). In the case of active site inhibitors, nucleos(t)ide
analogs possess pan-genotypic antiviral activity and have a higher
barrier to resistance than protease inhibitors (McCown et al., 2008).
Studies on sofosbuvir have not identiﬁed treatment failures due to
S282T in phase 3 clinical trials (Jacobson et al., 2013; Kowdley et al.,
2013; Lawitz et al., 2013a, 2013b; Rodriguez-Torres et al., 2013;
Donaldson et al., 2015; Margeridon-Thermet et al., 2014; Maimone
et al., 2014); however, NS5B binding-pocket mutations, such as S282T,
have developed in cell culture under sofosbuvir selection. In the
context of the many new DAAs it is important to obtain population
level data on HCV drug resistance mutations (DRMs) among
treatment-naïve subjects to identify mutations that affect treatment
outcome and to determine what baseline resistance testing is needed.
Next generation sequencing (NGS) provides massive, clonal,
ultra-deep sequencing that identiﬁes minority variants, undetect-
able through Sanger sequencing. NGS of the HCV NS3 gene has
demonstrated the dynamic transition of low abundance DR variants
(LADRV) into the dominant genotype following implementation of
protease inhibitors (Svarovskaia et al., 2012; Verbinnen et al., 2010).
Improved specimen ﬂow-through can be obtained through batch
analysis of specimens using tagged pooled pyrosequencing (TPP). By
combining DNA barcoding technology with 454 pryosequencing,
large numbers of viral specimens can be sequenced at a fraction of
the cost of conventional methods making large-scale resistance
testing feasible (Ji et al., 2010, 2013a, 2013b). This study demon-
strates how TPP technology can be used, in a public health context,
to determine the prevalence of NS5B DRMs among a challenging
and under sampled cohort of patients: mono and dually infected
(HIV/HCV) intravenous drug users (IDUs). Novel polymorphisms
identiﬁed as low-frequency variants were analyzed using in silico
tools to identify and evaluate novel variants with potential resis-
tance proﬁles.
Results
Cohort characteristics
All 127 specimens were successfully TPP sequenced and the
derived reads aligned to reference sequences of the pre-determined
HCV genotypes (Pilon et al., 2011). Estimated cost for genotyping for
each specimen was $45 (Ji et al., 2013b). The characteristics of the
cohort studied are summarized in Table 1. The majority of indivi-
duals were infected with genotype 1a (GT1a), although genotypes
1b, 2a, 2b and 3a were also found. Twenty-one (16.5%) subjects
were co-infected with HIV-1. Data on previous HCV treatment was
not collected. The average duration of intravenous drug use was
more than two decades.
TPP performed with high coverage and low error rate
The average TPP read redundancy was 3120 for nucleotides 7603–
9378 (AA 220–345) in the NS5B gene fragment. The cumulative error
rate from PCR and the pyrosequencing process, as determined by TPP
results from the control plasmid, was 0.0062 changes/nucleotide
position. Not surprisingly, higher error rates were observed in the
homopolymeric nucleotide runs and their ﬂanking loci (data not
shown). However, none of the detected NS5B variants were affected
by homopolymeric errors. Error rates at variant positions were
signiﬁcantly lower (0.0013 changes/nucleotide position) than those
found at other positions. Based on these observations, a conservative
frequency cutoff of 1% was set for low abundance variant identiﬁca-
tion in this study.
RBV/IFN resistance mutations identiﬁed by TPP
Although the treatment status of our cohort was unknown, the
proportion of inner city residents receiving HCV treatment in Canada
has historically been very low (Grebely et al., 2009). Inferring that
495% of this cohort would be treatment naive; we sought to use TPP
to evaluate the prevalence of polymorphism that affect outcomes
with RBV/IFN treatment. While no single resistance mutation has
been associated with resistance to interferon (Kuntzen et al., 2008),
12 RBV/IFN associated mutations were detected by TPP at frequencies
ranging from 1.2% to 100% with signiﬁcant variation between
genotypes (Table 2). For example, D310N (Asahina et al., 2005) was
detected in 26/28 (92.9%) of GT3a and 22/84 (26.2%) of GT1a, but was
not observed in isolates from any other genotype. In another
instance, T329I was detected in 4/28 (14.3%) of GT3a and 1/4 (25%)
of GT1b, while not observed elsewhere. K254R was reported pre-
viously to be co-selected by RBV with mutations such as D375G,
F415Y, and Q544R (Young et al., 2003). In our analysis the K254R
phenotype was detected in 11.8% of the studied subjects, including all
four GT1b isolates and 11/84 (13.1%) of GT1a (Table 2). We also
observed mutations correlated with a sustained virologic response
(Asahina et al., 2005; Hamano et al., 2005). For example, D244N was
observed in 25/28 (89.3%) of GT3a subjects, while A333E was only
detected in all GT2a and GT2b subjects. Q309R was observed in 27/28
(96.4%) of GT3a and 29/84 (34.5%) of GT1a, while not found in the
other three genotypes. S326G was identiﬁed in only 14/84 (16.7%) of
GT1a and 1/28 (3.6%) of GT3a. These data demonstrate that there is a
high prevalence of, and signiﬁcant inter-genotypic variation in,
polymorphisms associated with differences in RBV/IFN treatment
outcomes. No signiﬁcant difference in the frequency of HCV poly-
morphisms, between the HIV-HCV co-infected and the HCV infected
subjects, was observed.
TPP did not detect NNI resistance mutations in AA 220–345 of NS5B
It has been predicted that mutations in the allosteric binding
pockets targeted by NNIs will be found more frequently, as they
have less of an effect on replicative ﬁtness (McCown et al., 2008).
Amino acid C316 is within the allosteric binding pocket of the
polymerase and is of particular interest, as mutations at this position
confer resistance to two distinct classes of NNIs, the benzimidazole
derivatives and the benzofurans (Mayhoub, 2012); and more
recently has been found in patients who have failed treatment with
sofosbuvir (Donaldson et al., 2015). However, consistent with the
ﬁndings of Kuntzen et al., who analyzed the same region with
Sanger sequencing, we did not detect minority NNI mutations
C316N/Y/S, which are classically associated with resistance to NNIs
such as HCV-796 and ABT-333 (Aloia et al., 2012; Howe et al., 2008;
Kuntzen et al., 2008; Poordad et al., 2014). In contrast, others have
reported mutations at this position ranging in frequency from 0.19%
to 91.6% (Alves et al., 2013; Bartels et al., 2013; Jaspe et al., 2012;
Kuntzen et al., 2008); however these discrepancies may be due to
the genotypic structure of the circulating viruses within particular
geographical locations.
Table 1
Characteristics of the studied subjects.
Male N¼107
Female N¼20
Age (years) 4378.9
Duration of drug use (years) 22.0710.6
HCV genotypes
1a 66.1% (N¼84)
1b 3.1% (N¼4)
2a 1.6% (N¼2)
2b 7.1% (N¼9)
3a 22.0% (N¼28)
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Variants detected at codon S282
The highly sensitive TPP platform enables detection and quantiﬁ-
cation of HCV LADRVs present at a frequency of 1% or greater. Even
with this technique, S282T, the primary mutation associated with
resistance to sofosbuvir and other HCV NIs (Aloia et al., 2012), was not
detected in any specimens. However, several other S282 variants were
detected at differing frequencies. For example, S282R and S282C were
each detected in one of the GT1a subjects at 4.42% and 4.87%,
respectively. S282G was detected in one GT3a patient at a frequency
of 7.77%, and an additional six GT1a samples at frequencies ranging
from 1.15% to 1.82%. With the majority of S282G/R/C variants identiﬁed
in GT1a subjects, we also examined the clade identities of the those
7 patients positive for S282G/R/C (Pickett et al., 2011). Phylogenetic
analysis using both the Sanger sequencing data and the TPP consensus
sequences (TPP20) showed that both 1a1 and 1a2 clades were present
in this group (1a1:1a2¼4:3). There was no speciﬁc pattern of
association between S282 variation and speciﬁc 1a clades. In addition,
Table 2
Inter-genotype difference of HCV variants detected by TPP (frequency41%).
Genotypes Percentage of mutant positive subjects in examined genotype groups (%)
239V 239L 244N 254R 300T 309R 309K 310N 321I 326G 329I 333E
1a (N¼84) 7.1 1.2 — 13.1 — 45.2 — 26.2 3.6 16.7 — 1.2
1b (N¼4) — — — 100 100 — — — — — 25 —
2a (N¼2) — — — — — — — — — — — 100
2b (N¼9) 11.1 — — — — — — — — — — 100
3a (N¼28) 67.9 — 89.3 — 100 96.4 3.6 92.9 — 3.6 14.3 —
—: not detected.
Fig. 1. Workﬂow of TPP based HCV NS5B genotyping.
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further analysis of the genotypes at “clade-informative sites” in the
S282G/R/C positive reads showed no correlation with membership in
either 1a1 or 1a2 clades (Pickett et al., 2011).
In silico modeling identiﬁes potential novel drug resistance mutations
We identiﬁed novel mutations S282C/G/R for which no cell-
culture or biochemical NI resistance data has been published. Our
data demonstrates that these mutations can be found in patients,
which is in agreement with the similar ﬁnding of Le Pogam et al.
(2010). We sought to further investigate their potential resistance
proﬁle utilizing a freely available program, I-TASSER, which can
model a protein sequence onto a speciﬁed template. We submitted
a genotype 1a sequence to be modeled on the NS5B template 1NB6.
The 1NB6 template offers the advantage that its structure contains
the sofosbuvir analog UTP at the active site. This structure contains
divalent metal ions, and therefore demonstrates how the incoming
UTP may access the active site, forming a ternary complex similar to
that, which is seen with HIV-1 reverse transcriptase (O’Farrell et al.,
2003). We compare these results to those obtained with the 4E7A
structure, which demonstrates NS5B in a pretranslocated state, with
a short primer-template and a terminal 20,30-ddC (Mosley et al.,
2012). Although both structures are considered less than ideal (Gotte,
2014; Karam et al., 2014), in the absence of a high-resolution
genotype 1a ternary structure chain-terminated with UTP, we felt
that the selection of these structures as templates was appropriate.
Having structures demonstrating a spectrum of potential conforma-
tions may even be preferred considering the elusiveness of how
substitutions at S282 confer decreased sensitivity to sofosbuvir.
Previous studies have demonstrated that S282T causes 9.5-fold
resistance to sofosbuvir (Lam et al., 2012). Thus it was not surprising
that although both serine and threonine have polar, uncharged side-
chains, the addition of a methyl group within threonine (Fig. 2A)
changes the orientation of the side-chain such that the impact of the
hydroxyl may change the orientation of the uracil. When examining
the S282R structure, our model demonstrates an obvious interaction
between the positively charged arginine and the hydroxyl group at
position 2 of the ribose, which (because of the ﬂexibility of the
inhibitor) could change the orientation of the speciﬁcity domain
required to chain terminate (Fig. 2B). With respect to positioning, the
cysteine of S282C (Fig. 2C) may have less of an effect than the
threonine, although it is difﬁcult to predict the contribution of a thiol
group in place of a hydroxyl group. Finally, as glycine is obviously
smaller than all previous side chains, we propose that S282G
(Fig. 2D) may have more serious effects on the resistance proﬁle of
sofosbuvir. This would likely be due to the change in polarity that
would occur in this region, and the potential effects this change may
have on the orientation of the base of the inhibitor. These results are
in agreement with those obtained using the 4E7A structure as a
template (Supplemental Fig. 2).
We also sought to investigate the potential synergistic impact of a
newly identiﬁed mutation, L159F (Donaldson et al., 2015; Tong et al.,
2014). L159F emerged in 6 genotype 3a subjects on sofosbuvir therapy
by deep-sequencing methods. It was also present at baseline in four
genotype 1b patients, who failed therapy; and of the on-treatment
failures, a 1b patient had L159F at baseline, and it emerged in a 2a and
two 1a patients. Depending on the patient and trial, the mutation was
classiﬁed as either a resistance-associated substitution as determined
by the FDA Division of Antiviral Products criteria, or resistance-
associated polymorphism present at baseline in subjects who failed
treatment (Donaldson et al., 2015). Our modeling data demonstrates
that when the leucine at 159 is replaced with a phenylalanine, the
orientation of the residue does not signiﬁcantly change, except in the
case of S282R/L159F (Fig. 3). In fact based on our data, for both S282T/
L159F (Fig. 3A) and S282C/L159F (Fig. 3C), the substitution at L159F
may lessen any potential interactions between sofosbuvir and a 282
variant, suggesting it may act as a compensatory mutation if found.
However, in the case S282R/L159F our model suggests that a steric
clash would occur between the arginine and the uracil, likely as a
result of the effect of aromatic side-chain of phenylalanine on the
charged arginine residue (Fig. 3B). In summary, based on our modeling
data (irrespective of the template used), and other deep-sequencing
Fig. 2. Modeling of active site S282 variants in NS5B genotype 1a. Overlay of UTP-bound (orange), 1NB6 (O’Farrell et al., 2003), and an I-TASSER generated genotype 1a HCV
NS5B containing (A) S282T, (B) S282R, (C) S282C, and (D) S282G. Mutations generated in I-TASSER are shown in green. The catalytic triad coordinates the two manganese
ions shown in purple.
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studies (Donaldson et al., 2015) we would prioritize further investigat-
ing S282G and S282R as single-mutants, and S282R/L159F with
respect to a potential double-mutant.
Minor HCV NI DRMs were detected at different frequencies among
genotypes
V321I, known to enhance resistance to NIs such as PSI-352938
and PSI-353661, was observed in three of 84 GT1a patients, with
frequencies at 5.89%, 1.27% and 1.17% respectively. This is in
agreement with Margeridon-Thermet et al. (2014) who found
V321I in one GT1a sample (Margeridon-Thermet et al., 2014). It
has also recently been shown that V321A may be associated with
treatment failure in sofosbuvir-experienced patients (Donaldson
et al., 2015). However, none of the other associated variants that
may synergize with V321I such as R222Q, C223Y/H and L320I,
were observed (Lam et al., 2011). It has been shown that L320F/C,
A300T, and I239L may be co-selected with S282T in vitro using
PSI-6130 and R7128 (Ali et al., 2008; Tong et al., 2014). In the case
of L320F, the mutation alone confers a 2.7-fold increase in in vitro
resistance and a 41-fold increase when present in conjunction
with S282T in vitro (Tong et al., 2014). Our results demonstrate
that the A300 site is highly polymorphic and that the phenotype at
this site is highly genotype-speciﬁc. T300 is the dominant pheno-
type in all GT1b and GT3a subjects, but the majority of GT1a
subjects have Q300, and all GT2a and 2b showed L300. Similarly,
the I239 site is also polymorphic with signiﬁcant inter-genotype
variations. I239L was observed in only one GT1a subject at fre-
quency of 2.10%, while I239V variants were detected in 26 subjects
with HCV GT3a, GT1b or GT1a (Table 2). The 320F/C phenotypes
were not detected in any of the studied subjects.
High concordance was observed between TPP and Sanger sequencing
Results from SS and TPP20 consensus sequences were highly
concordant with the prevalence of mutations within the cohort
being nearly identical (Table 3). The only exceptions were muta-
tions at D244N, K254R and Q309R, which were each identiﬁed by
SS; however the measured TPP mutation frequencies were 16.2%,
15.6% and 12.6% respectively. Thus, if the threshold for TPP
reporting was set at 20%, these mutations would not have been
identiﬁed; however, this did not signiﬁcantly affect the prevalence
of HCV DR within the cohort.
Discussion
Surveillance of populations to identity the baseline prevalence of
HCV DRMs, such as S282T, is important for providing data upon
which to make therapeutic and policy decisions. Although deep
sequencing has been utilized to study NS5B regions, these studies
either failed to look for DRMs; used small cohorts of HCV/HIV
co-infected individuals; or were limited by HCV subtype homogene-
ity (Franco et al., 2013; Maimone et al., 2014; Margeridon-Thermet et
al., 2014; Wu et al., 2013). Recent work by Tong et al. (2014) identiﬁed
Fig. 3. Modeling of active site S282 variants with L159F in NS5B genotype 1a. Overlay of UTP-bound (orange), 1NB6 (O’Farrell et al., 2003), and an I-TASSER generated
genotype 1a HCV NS5B containing (A) S282T/L159F, (B) S282R/L159F, (C) S282C/L159F, and (D) S282G/L159F. Mutations generated in I-TASSER are shown in green. The
catalytic triad coordinates the two manganese ions shown in purple.
Table 3
Average prevalence (%) of HCV variants in the cohort while varied frequency cutoffs
were applied.
Mutant phenotype TPP1 TPP5 TPP10 TPP20 Sanger sequencing
I239V 20.5 7.1 1.6 0 0
I239L 0.8 0 0 0 0
D244N 19.7 19.7 19.7 18.9 19.7
K254R 11.8 7.9 7.1 6.3 7.1
A300T 25.1 25.1 25.1 25.1 25.1
Q309R 51.2 44.1 44.1 43.3 44.1
Q309K 0.8 0.8 0.8 0.8 0.8
D310N 37.8 37.8 37.8 37.8 37.8
V321I 2.4 0.8 0 0 0
S326G 11.8 1.6 0.8 0 0
T329I 3.9 2.4 2.4 1.6 1.6
A333E 9.4 8.7 8.7 8.7 8.7
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mutations that may play a role in resistance to NS5B inhibitors, and
highlighted the need to identify potential novel DRMs that require
surveillance. Additionally, Donaldson et al. (2015) recently identiﬁed
several novel mutations observed in patients who failed sofosbuvir-
containing therapy (Donaldson et al., 2015).
The S282T mutation is associated with relapse in sofosbuvir
monotherapy treatment (Gane et al., 2013; Svarovskaia et al., 2014),
however, as the baseline genotype was not reported, whether the
S282T mutation existed prior to treatment remains undetermined.
While a recent small study found a single patient with S282T
following sofosbuvir plus ribavirin therapy (Osinusi et al., 2014),
larger trials involving patients with HCV genotypes 1, 2 and 3 failed
to ﬁnd the S282T mutation among treatment-experienced and naïve
individuals (Gane et al., 2013; Jacobson et al., 2013; Lawitz et al.,
2013a, 2013b; Applegate et al., 2014; Donaldson et al., 2015; Maimone
et al., 2014; Margeridon-Thermet et al., 2014; Svarovskaia et al., 2014).
Our data is in agreement with these large studies in that we did not
ﬁnd evidence of S282T through either SS or at lower frequencies or by
using TPP sequencing. It has been shown in cell culture that S282T
results in decreased viral ﬁtness (Ludmerer et al., 2005) and our
inability to detect the mutation in our cohort is consistent with this
mutation being associated with a high ﬁtness cost.
Using TPP wewere able to detect minor variant species at the S282
locus, including S282G, S282R and S282C. Although in vitro studies
often indicate reduced viral ﬁtness of drug resistance mutations,
Kuntzen et al. demonstrated viral ﬁtness may be unimpaired in
individual situations, perhaps as a result of compensatory mutations
(Kuntzen et al., 2008). Reduced or weak enzymatic activity may also
occur during biochemical analysis, as has been shown for S282R. This
decrease in ﬁtness was also the case when Le Pogam et al. (2010)
detected S282G and S282R through clonal sequencing among patients
on monotherapy with the nucleoside inhibitor RG7128. When asses-
sing the ﬁtness of these variants this group was unable to obtain
replication competent-viruses when introducing these mutations
through site-directed mutagenesis. They were, however, able to
propagate isolated clones (Le Pogam et al., 2010). As these mutations
have now been found by our group as well as others (including under
drug selective pressure) (Donaldson et al., 2015; Franco et al., 2013;
Maimone et al., 2014), we are conﬁdent that viruses containing S282R
or S282G are ﬁt enough to survive, and therefore warrant further
investigation. We ﬁnd it especially interesting, that Donaldson et al.
(2015) detected S282R in a patient who failed a sofosbuvir-containing
regimen. As S282C and S282G require only a single transition to from
S282R, the importance of these variants may also include the potential
to be springboard mutations (Powdrill et al., 2011).
Selection experiments with NIs PSI-6130 and R7128 suggested
that other mutations, including I239L/T, L320F/L/C and A300T,
might be co-selected and synergize with S282T by enhancing
resistance to the aforementioned compounds (Ali et al., 2008;
Tong et al., 2014). Our data indicates that, in the absence of S282T,
low frequency I239L is detected in only 1/127 subjects and there
was no evidence of 320F/C in the cohort. These ﬁndings support
the hypothesis that both mutations are co-selected with S282T
during treatment with NIs (Ali et al., 2008). However, T300 was
observed as the dominant phenotype in HCV GT1b and GT3a
subjects, while the majority of GT1a subjects have Q300, and all
GT2a and 2b showed L300. Therefore, we believe that A300T
represents primarily an inter-genotype polymorphism rather than
positively co-selected drug resistance variation. Nevertheless,
further investigation is required to determine the exact role of
these variants in viral ﬁtness and drug resistance, especially when
more compounds of this class are made available in the clinic. Our
TPP data indicated that many of the patients within the cohort had
at least one variation, or polymorphism, known to confer resis-
tance to RBV/IFN combination (Asahina et al., 2005; Hamano et al.,
2005; Jaspe et al., 2012). These ﬁndings may help to explain part of
the variability observed in treatment outcomes using IFN based
therapies. We employed I-TASSER as a predictive modeling
method in order to better understand the mechanism of resistance
of S282 polymorphisms, using two well-deﬁned crystal structure
templates. Despite differences in the genotype, deletions, and
overall conformation (open versus closed) (Mosley et al., 2012;
O’Farrell et al., 2003), the interaction between variants at S282 and
the UTP (or terminal nucleotide) remains consistent, and allows
for the prioritization of substitutions for further biochemical study.
Residues in close proximity to S282 may help to coordinate UTP
and, by corollary, sofosbuvir. The spatial and charge-related amino
acid changes observed in the S282G/R/C variants may affect
sofosbuvir binding in a similar manner to S282T. However, the
speciﬁcity domain of sofosbuvir may also be able to easily
reposition resulting in no change in the overall afﬁnity of inhibitor
binding. In order to deﬁnitively predict these types of outcomes
expensive dynamic modeling software and high-processing com-
puters would be required. In our study, generating static models of
drug resistance mutations is a cost-effective, relatively simple ﬁrst
step that may help predict sites of drug resistance that are
oriented around polymorphisms. This later point is more signiﬁ-
cant in that the S282G mutation was found among several
sequences suggesting that it is stable and thus may be transmis-
sible. From a clinical perspective, detecting this polymorphism as a
minority variant previously undetectable by conventional meth-
ods, may provide more insight into cases of clinical failure. As the
clinical use of sofosbuvir increases, the collective in vivo selective
pressure will correspondingly increase and thus allow us to
validate the drug resistance predications by using this technique.
In conclusion, we have successfully demonstrated that TPP is a
cost-effective (Ji et al., 2010, 2013b), advanced NGS platform that
can be used to evaluate HCV drug resistance. We have demon-
strated that TPP allows population/cohort level HCV DR surveil-
lance analysis by generating consensus sequences comparable to
standard methods. The role of minority variants detected using
TPP in treatment outcome remains to be determined. Through
pooling multiple specimens in a single pyrosequencing run, HCV
genotyping can be performed more efﬁciently and at cost sig-
niﬁcantly lower than conventional methods (Ji et al., 2010, 2013b).
Recognizing potential limitations from pyrosequencing method,
we have conﬁrmed in a separate study that the TPP approach
described here is fully adaptable for other NGS technologies, such
as Illumina MiSeq (data not shown). Combining pooled NGS with
molecular modeling provides an approach to explore potentially
drug resistant polymorphisms that may manifest as clinical failure
under drug pressure.
Materials and methods
Subjects and specimens
A total of 127 specimens were selected, from a previously
described Ottawa cohort of IDUs based upon specimen availability
and single HCV genotype (GT) infection (Pilon et al., 2011). No
information was available on previous treatment history or HCV
viral loads. This study was approved by the institutional Research
Ethics Board.
HCV NS5B sequencing with TPP approach
Fig. 1 outlines the TPP workﬂow for HCV NS5B sequencing (Ji
et al., 2013b). In brief, HCV RNA was extracted from dried blood
spot (DBS) specimens using the Nuclisens EasyMag system (Boom
et al., 1990). The HCV NS5B gene fragment encompassing the palm
and partial ﬁnger domains was reverse transcribed and ampliﬁed
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using Qiagen One step RT-PCR kit (Love et al., 2003; Pilon et al.,
2011). Following RT-PCR, one round of nested-PCR was performed
using customized fusion primers, employing the 454 Lib-L tem-
plate while the reverse primers tagged with patient-speciﬁc MIDs
(Ji et al., 2013b). The template-speciﬁc primer sequences for the
fusion primers were: NS5B-in.for: IACYATCATGGCIAARARYGAGGT;
and NS5B-in.rev: ACCTRGTCATAGCCTCCGTGAA (Pilon et al., 2011).
The resulting 600 bp amplicon spanned the majority of relevant
mutation loci related to sofosbuvir and RBV/IFN treatments. The
amplicons were puriﬁed, quantiﬁed, and then pooled at equimolar
concentrations with those from other subjects (Ji et al., 2013b). The
pooled templates were then clonally ampliﬁed using Roche emul-
sion PCR (Lib-L) kit, and loaded onto picotiterplate ﬁtted with an
8-lane gasket for unidirectional pyrosequencing with the GS FLX
Titanium kit (Roche, USA).
Sequence analysis
All TPP reads satisfying the GS FLX default quality screening criteria
were then decoded by patient-speciﬁc MIDs using an in-house Perl
Script. Sequence contigs were then generated for each individual
subject using specimen speciﬁc HCV GT references (Genbank accession
numbers: 1a: NC004102; 1b: AJ238800; 2a: AB047639; 3a: AY51526.1)
(Pilon et al., 2011). All reads were subjected to an in-house second
round of quality screening with TPP reads considered valid only if they
were Z100 bp in length and mapped to the reference sequence with
both 60% overlap and Z75% identity. The overall empirical TPP error
rate was assessed by PCR amplifying and pyrosequencing in parallel a
pedigreed H77 Delta E1-p7 replicon plasmid construct (a kind gift
from Dr. Selena Sagan, Stanford University).
Based on the translated sequence alignments, all amino acid (AA)
changes previously been associated with anti-HCV regimens or
compounds were examined and quantiﬁed using BioEdit 7.0.9 (Hall,
1999). The inter-group comparisons among HCV genotypes were
further assessed for all AA variants. The frequencies of TPP-based AA
variants were also compared with Sanger sequencing (SS) results
obtained previously (Pilon et al., 2011). To facilitate the comparison of
the TPP with SS results, we reported a variant or DRM if it was present
in 20% of the TPP reads (TPP20). To demonstrate the capacity of TPP to
detect LADRV, TPP consensus sequences with three lower variant
frequencies (TPP1, TPP5, and TPP10) were also examined.
In silico modeling
In order to assess the potential impact on sofosbuvir activity of
low frequency polymorphisms located within the NS5B active site,
we developed in silico models using NS5B crystal structures contain-
ing uridine-50-triphosphate (UTP). We submitted full-length geno-
type 1a sequences to the I-TASSER online server, which predicts
protein structure and functions (Roy et al., 2010, 2011; Zhang, 2008).
Rather than allowing the server to use the most related crystal
structure in the database as a reference, we stipulated it use the HCV
NS5B structure 1NB6 (O’Farrell et al., 2003) to identify potential
interactions. As a structure with sofosbuvir bound has not yet been
published, we felt this was an appropriate substitute as there is the
presence of a terminal UTP, representing what would be the
speciﬁcity domain of the inhibitor (corresponding to the base region
of UTP) is in close proximity to the S282 position. This type of
modeling is unique in that it does not require sophisticated software.
Furthermore, we validated our chosen template structure by demon-
strating that the positions of the active site residues are in agreement
with other accepted crystal structures that have been used to model
potential relationships between S282 and sofosbuvir (Supplemental
Fig. 1) (Donaldson et al., 2015), as well as with the more recently
published structure 4E7A (Supplemental Fig. 2) (Mosley et al., 2012).
Tertiary alignments were carried out using USCF Chimera.
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